A lot smaller upfront payment than first thought·
Initial consideration value of US$10 million, which includes non-dilutive equity in the SPV;
Ajan Reginald, Roquefort Therapeutics CEO commented:"We are pleased to announce this therapeutic licencing deal with an initial payment which is likely to include $1.25-2.5M upfront and a 24% share of what is substantial potential upside.
A lot smaller upfront payment than first thought· Initial...
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.768M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.6¢ | $11.31K | 1.886M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1650000 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 915710 | 1 |
View Market Depth
| Last trade - 14.23pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.6¢ |
Change
0.000 ( 14.3 %) |
||||
| Open | High | Low | Volume | ||
| 0.6¢ | 0.6¢ | 0.6¢ | 287949 | ||
| Last updated 14.34pm 14/06/2024 ? | |||||
| AN1 (ASX) Chart |